跳至主要内容
临床试验/IRCT201702131457N12
IRCT201702131457N12招募中3 期

Evaluation of efficacy and safety of Haloperidol on symptoms of acute opioids withdrawal

Mazandaran University of Medical Sciences0 个研究点目标入组 74 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
招募中
入组人数
74

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 60 years(—)
性别
All

入选标准

  • A reliable history of opioids consumptions until the onset of the study; DSM-5 criteria for opioid use disorder; Positive urine rapid test of opioids
  • Exclusion criteria:Enzyme inducers medication usage or other medical treatments;History of Sensitivity to haloperidol; Poly substance use (Cannabinoids ,Alcohol , barbiturates , benzodiazepines, analgesics) and use of antidepressants , other antipsychotics , beta blockers , alpha 2 agonists, inhibitors of CYP 3A4 , and CYP2D6 in the last month before study (except nicotine); Major depressive disorder, Bipolar mood disorder, severe anxiety disorders and Psychosis; Severe medical illnesses such as epilepsy, hepatitis, tuberculosis, AIDS, liver dysfunction, renal dysfunction; Pregnancy and Lactation; Electroconvulsive therapy in the last 6 months; Suicidal ideation or suicidal attempt at the beginning of the study or within the last 6 months; Mental retardation; Neurological disorder such as dementia, uncontrolled epilepsy and history of head trauma ; Past history of neuroleptic malignant syndrome.

排除标准

  • 未提供

研究者

相似试验

Efficacy of haloperidol on symptom of opium... | 临床试验